Monitoring of Thromboembolic Events Prophylaxis: Where Do We Stand?

Laleh Mahmoudi, Soha Namazi, Shiva Nemati, Ramin Niknam

Abstract


Background: Thromboembolic events are one of the most important causes of mortality in the hospitalized patients. Evaluation of anticoagulants intake patterns compared to the standard treatment guidelines is necessary for improving the quality of prophylaxis managements. The present study was performed to evaluate the pattern of heparin and enoxaparin intake compared to the standard treatment guidelines for thromboprophylaxis.

Methods: The present study was conducted on 305 patients admitted to the two referral teaching hospitals. The patients were classified according to the treatment guidelines of American College of Chest Physicians and based on the type of risk (low, moderate, and high). Finally, prophylaxis regimen was assessed based on the standard treatment guidelines and the intervention was performed in case of contradiction.

Results: In this study, averagely, prophylactic regimen showed 83.3% compliance with the standard treatment guidelines. Moreover, 188 patients (61.6%) were in moderate and high risk groups and needed prophylaxis therapy. Among these patients, 93% (175 patients) received appropriate prophylaxis. According to the results, being above 40 years old, infection, and inactivity were the most important risk factors in the patients with the prevalence of 81.6%, 47.9%, and 43.3%, respectively.

Conclusion: Although treatment guidelines are available for the prophylaxis of thromboembolic events, prophylaxis regimens are not always administered in accordance with these guidelines. Failure to observe these guidelines could increase the cost of treatment and risk of thrombosis as well as other serious problems for the patients.




J Hematol. 2015;4(4):223-227
doi: http://dx.doi.org/10.14740/jh232e



Keywords


Anticoagulation protocol; Heparin; Enoxaparin; Prophylaxis; Guideline

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)



This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
 

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!